Aripiprazole Treatment of Prodromal Patients

Yale University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Psychosis; Schizophrenia

Treatments: Drug: Aripiprazole

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00237874

YaleHIC26037

Details and patient eligibility

About

We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.

Full description

This is an 8 week trial with extension for responders out to one year. All patients receive active medication; there is no placebo. Patients must meet criteria for the schizophrenia prodrome according to the Structured Interview for Prodromal Syndromes. Patients receive counseling as well. All counseling and medication are free of charge.

Enrollment: 15 patients

Sex: All

Ages: 13 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 13 to 40 meet criteria for the prodrome for schizophrenia

Exclusion criteria

• history of psychosis

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)